HIM
ARQT icon

Hillsdale Investment Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Hillsdale Investment Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.43M Buy
188,220
+8,800
+5% +$225K 0.12% 217
2025
Q4 		$5.21M Buy
+179,420
New +$4.59M 0.14% 192

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hillsdale Investment Management's ARQT Position: Q1 2026 in Review

Hillsdale Investment Management increased its Arcutis Biotherapeutics (ARQT) stake by 4.9% in Q1 2026, buying an estimated $225K and bringing the position to 188,220 shares worth $4.43M. The position accounts for 0.12% of the portfolio, ranked #217.

Hillsdale Investment Management first reported a position in ARQT in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.21M in Q4 2025. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Hillsdale Investment Management held 188,220 shares of Arcutis Biotherapeutics worth $4.43M as of Q1 2026.
  • Hillsdale Investment Management bought 8,800 Arcutis Biotherapeutics shares in Q1 2026, an estimated $225K.
  • Arcutis Biotherapeutics made up 0.12% of Hillsdale Investment Management's portfolio in Q1 2026, its #217 holding.
  • Hillsdale Investment Management first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • Hillsdale Investment Management's Arcutis Biotherapeutics position peaked at $5.21M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.